Results 1 to 10 of about 75,785 (301)

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity [PDF]

Cancers, 2021
CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body. Our goal was to develop exosomes expressing CD19 CAR to treat CD19-positive B-cell malignancies, instead of using whole CD19 CAR-T cells, thereby reducing the clinical risk of uncontrolled
Shabirul Haque
exaly   +3 more sources

Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in treating B-cell malignancies, including acute lymphoblastic leukemia (B-ALL).
Jennifer Bolsée, Benjamin Violle, Céline Jacques-Hespel, Thuy Nguyen, Caroline Lonez, Eytan Breman   +5 more
doaj   +3 more sources

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC [PDF]

, 2012
PMCID: PMC3526610This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trojan, AD Hamblin, AG Ramsay, AG Ramsay, AM Krackhardt, AP Kater, AP Kater, BL McClune, C Haller, C Mayr, C Nabhan, CA Rodrigues, D Bagnara, D Dilloo, D Wolf, D Xing, DA Mavroudis, DL Porter, Dongxia Xing, Elizabeth J. Shpall, Hiroshi Shiku, Hong Yang, I Ben-Bassat, I Hus, IF Khouri, J Chen, Jeffrey J. Molldrem, JG Gribben, JG Gribben, JM Rudolph, John G. Gribben, JS Miller, K Kato, M Hoogendorn, M Ritgen, MA King, Matthew M. Halpert, MF Bachmann, Michael J. Keating, N Shah, Nina Shah, R Le Dieu, R Mous, Ruth Lapushin, S Miscia, S Parmar, S Samarasinghe, Simon N. Robinson, Simrit Parmar, SL Martins, SM Schmidt, Sufang Li, T Nishida, WG Wierda, William G. Wierda, William K. Decker, WK Decker   +56 more
core   +23 more sources

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.

PLoS ONE, 2021
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely.
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert   +10 more
doaj   +1 more source

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells

International Journal of Nanomedicine, 2023
CAR-T cell therapy is effective in the treatment of certain hematological malignancies, and the expansion and functional persistence of CAR-T cells in vivo are crucial to clinical efficacy. The aim of this study was to investigate the potential of extracellular vesicles (EVs) modified with the CAR antigen to promote the efficacy of CAR-T cells in vivo ...
Yuanyuan Zhang, Tong Ge, Meijuan Huang, Yun Qin, Tianjiao Liu, Wei Mu, Gaoxiang Wang, Lijun Jiang, Tongjuan Li, Lei Zhao, Jue Wang   +10 more
openaire   +4 more sources

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors [PDF]

Journal of Translational Medicine, 2013
Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis,
De Oliveira, SN, Wang, J, Ryan, C, Morrison, SL, Kohn, DB, Hollis, RP   +5 more
openaire   +6 more sources

Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy

Molecular Therapy: Oncolytics, 2020
Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens.
Amin Aalipour, Fabrice Le Boeuf, Matthew Tang, Surya Murty, Federico Simonetta, Alexander X. Lozano, Travis M. Shaffer, John C. Bell, Sanjiv S. Gambhir   +8 more
doaj   +1 more source

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies [PDF]

Journal of Clinical Investigation, 2016
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients ...
Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, Jan J. Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill   +20 more
openaire   +2 more sources

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor [PDF]

Journal of Immunotherapy, 2009
T cells can be engineered to express the genes of chimeric antigen receptors (CARs) that recognize tumor-associated antigens. We constructed and compared 2 CARs that contained a single chain variable region moiety that recognized CD19. One CAR contained the signaling moiety of the 4-1BB molecule and the other did not.
James N, Kochenderfer, Steven A, Feldman, Yangbing, Zhao, Hui, Xu, Mary A, Black, Richard A, Morgan, Wyndham H, Wilson, Steven A, Rosenberg   +7 more
openaire   +2 more sources

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19 [PDF]

Nature Communications, 2022
AbstractWhile chimeric antigen receptor (CAR) T cells targeting CD19 can cure a subset of patients with B cell malignancies, most patients treated will not achieve durable remission. Identification of the mechanisms leading to failure is essential to broadening the efficacy of this promising platform.
Amanda Heard, Jack H. Landmann, Ava R. Hansen, Alkmini Papadopolou, Yu-Sung Hsu, Mehmet Emrah Selli, John M. Warrington, John Lattin, Jufang Chang, Helen Ha, Martina Haug-Kroeper, Balraj Doray, Saar Gill, Marco Ruella, Katharina E. Hayer, Matthew D. Weitzman, Abby M. Green, Regina Fluhrer, Nathan Singh   +18 more
openaire   +4 more sources